Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Inmune Bio ( (INMB) ) is now available.
On December 22, 2025, INmune Bio Inc. amended certain investor warrants issued in its April 24 and April 29, 2024 offerings, adjusting the terms on 1,348,315 outstanding warrants. The company reduced the exercise price of these April 2024 warrants to $1.95, a level above Nasdaq’s defined minimum price as of December 17, 2025, and extended their expiration date to June 30, 2026, in exchange for a $0.05 per warrant payment, generating $67,416 in proceeds and potentially improving the warrants’ attractiveness to holders while modestly strengthening the company’s near-term funding flexibility.
The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
Spark’s Take on INMB Stock
According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.
Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.
To see Spark’s full report on INMB stock, click here.
More about Inmune Bio
INmune Bio Inc. is a biotechnology company, with its shares listed on Nasdaq, that raises capital in part through warrant offerings to investors.
Average Trading Volume: 412,170
Technical Sentiment Signal: Sell
Current Market Cap: $48.65M
For a thorough assessment of INMB stock, go to TipRanks’ Stock Analysis page.